MAPT and Alzheimer disease: Specific plasma p-tau variants (i.e., phosphorylated at different epitopes) may increase distinctly in response to different AD pathophysiological processes, but increases in their levels in AD seem to be associated with the presence of Aβ pathology [8–11].